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Aims of the present study 
 
Caspases are a group of proteases that cleave intracellular substrates and thereby regulate the 
process of apoptosis. Growth factors can protect cells against apoptosis via the mitogen-
activated protein kinase/extracellular-signal regulated kinase (MEK/ERK) signalling pathway. 
The production of reactive oxygen species can stimulate cytochrome c (cyt c) release and 
activate downstream caspase signalling pathways that lead to apoptosis.  The focus of this 
work has been the interaction between epidermal growth factor (EGF) and caspase-3 as well 
as the crosstalk between ROS and caspase-3. These subjects were investigated using reported 
caspase-3 activators and apoptosis-inducing agents as experimental tools in chicken cerebellar 
granule neurons (CGN) and phaeocyhromocytoma (PC12) cells. 
The specific aims of the present study are: 
1. To investigate pro-caspase activating compound-1 (PAC-1) as a zinc chelator and 
caspase-3 activator in chicken CGN (Paper I). 
2. To investigate the neurotoxicity of PAC-1 and proenzyme activator 1541 (1541) in 
chicken CGN and PC12 cells and establish these cells as model systems to study these 
compounds (Papers I and II). 
3. To investigate the effects of growth factors such as EGF on the cell-death-inducing 
properties of PAC-1 and 1541 in PC12 and chicken CGN cells (Paper II).   
4. To investigate the toxicity of combretastatin A-4 (CA-4) and triazole analogues in 
PC12 cells and to examine the crosstalk between caspase-3 activation and ROS 
production (Paper III). 
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1. Introduction 
1.1 Cell death 
 
Cell death is an integral part of development in all organisms (Penaloza et al., 2006) and has 
begun even by the time the embryo consists of just eight cells. Many cells die during the 
processes of development, homeostasis and aging (Lockshin and Zakeri, 2007). Cell death can 
be exploited to kill tumours; chemotherapeutic agents, ɣ-irradiation, suicide genes and 
immunotherapy have been shown to induce apoptotic cell death. Although many pathways 
with unique mechanisms and morphologies can result in cell death, they can be grouped into 
three major types: apoptosis, necrosis and oncosis. In the 19th century, naturally occurring 
cell death was first described. The term apoptosis was introduced in 1972 (Kerr et al., 1972), 
and the concept of physiological cell death was received with acclaim (Chimienti et al., 
2001). Cell death is an essential strategy to control of the dynamic balance in living systems 
(Vermeulen et al., 2005). Complex multicellular organisms maintain a delicate balance 
between growth and cell death; perturbation of this balance can result in neoplasia or 
neurodegeneration (Crawford and Wells, 2011). 
1.2 Apoptosis 
 
Programmed cell death, or apoptosis, is a continuous, non-inflammatory physiological process 
and is an active field of biochemical research (Schultz and Harrington, 2003). Apoptosis is a 
crucial mechanism for organism survival and is functionally conserved in all higher 
eukaryotes. This important process is responsible for the removal of damaged or infected cells 
from the cellular population, which links apoptosis to the cell cycle, replication and DNA 
repair. Moreover, apoptosis is one of the main mechanisms governing accurate embryonic 
development and the maintenance of tissue homeostasis (Pecina-Slaus, 2009). Although 
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apoptosis is an essential process, it is also involved in a wide range of pathological conditions 
(Zimmermann et al., 2001).   
The deregulation of apoptosis is an important factor in pathological conditions such as cancer 
and autoimmune and neurodegenerative diseases. Apoptotic cells can be characterised by 
specific morphological and biochemical changes, including cell shrinkage, chromatin 
condensation, and the internucleosomal cleavage of genomic DNA. At the molecular level, 
apoptosis is tightly regulated and mainly orchestrated by the activation of an aspartate-
specific cysteine protease (caspase) cascade (Zimmermann et al., 2001). Two main pathways 
lead to caspase activation (Figure 1). The first of these pathways depends on mitochondrial 
participation (receptor-independent), and the second involves the interaction of a death 
receptor with its ligand.  
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Fig 1. Schematic representation of apoptotic events. Apoptosis is induced by an extrinsic, 
intrinsic or perforin/granzyme pathway. Each pathway requires specific signals to trigger an 
energy-dependent cascade of molecular events. Each pathway activates its own initiator 
caspase (8, 9, or 10), which in turn activates the executioner caspase-3. However, granzyme A 
functions in a caspase-independent fashion. The execution pathway results in characteristic 
cytomorphological features including cell shrinkage, chromatin condensation, the formation 
of cytoplasmic blebs and apoptotic bodies and finally phagocytosis of the apoptotic bodies by 
adjacent parenchymal cells, neoplastic cells or macrophages. Figure and legend from 
(Elmore, 2007). 
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1.3 Caspases 
 
Caspases are a family of intracellular proteases involved in inflammation and are also crucial 
mediators of programmed cell death (Porter and Janicke, 1999). Once activated by a specific 
stimulus, caspases perform limited proteolysis of downstream substrates to trigger a cascade 
of events that culminates in specific biological responses (Pop and Salvesen, 2009). Caspase 
zymogens are single chain proteins with N-terminal prodomains preceding the conserved 
catalytic domains. Two zymogens are cleaved to create two small and two large subunits that 
assemble into heterotetramers (Figure 2).  
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Fig 2. Schematic overview of the apoptotic pathways. Engagement of the extrinsic or 
intrinsic death pathways leads to the activation of the initiator caspases by dimerisation at 
multiprotein complexes. In the extrinsic pathway, the DISC is the site of activation for 
caspase-8 and, at least in humans, caspase-10. The active sites are represented by orange stars. 
Stimulation of the intrinsic pathway leads to activation of caspase-9 at the apoptosome. 
Caspase-9 is shown as having one active site as seen in its crystal structure. However, the 
number of active sites in vivo is unknown. Following activation, the initiator caspases then 
cleave and activate the executioner caspases-3 and -7. Figure and legend from (Boatright and 
Salvesen, 2003). 
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1.3.1 Classification 
 
Caspases are classified into two main groups: apoptotic (caspase-2, -3, -6, -7, -8, -9, and -10) 
and pro-inflammatory (caspase-1, -4, -5, -11, -12 and -13). The apoptotic caspases are further 
categorised as initiators (caspase-2, -8, -9 and -10) or effectors (caspase-3, -6 and -7) (Pop and 
Salvesen, 2009). 
1.3.2 Mechanism of activation 
 
Caspases are synthesised as inert zymogens that are subsequently activated by internal or 
external apoptotic stimuli. Once these stimuli occur, cells activate initiator caspases that 
proteolytically cleave and activate effector caspases. Once active, this second set of caspases 
is capable of cleaving a large number of substrates that ultimately lead to cell death. 
Procaspases contain an N-terminal prodomain and sequences encoding the large (p20) and 
small (p10) subunits of procaspase (Kurokawa and Kornbluth, 2009) (Figure 3). Caspases 
specifically recognise a tetrapeptide sequence on their substrate with an absolute requirement 
of an Asp residue (Vermeulen et al., 2005). The two major apoptotic pathways can be 
differentiated by the cyt c release from the mitochondria. In the intrinsic pathway, cyt c is 
released from the mitochondrial intermembrane spaces prior to caspase activation, and in the 
external pathway, it may be released after the activation of effector caspases by the activation 
of death receptors (Lossi and Gambino, 2008). 
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Fig 3. Caspase organisation. A, a prodomain precedes the catalytic domain, which is 
composed of two covalently linked subunits. Sites for (auto) proteolysis at Asp residues are 
indicated. B, activation mechanisms. Initiators are monomers that activate by prodomain-
mediated dimerisation. Executioners are dimers that activate by cleavage of intersubunit 
linkers. Following activation, additional proteolytic events mature the caspases to more stable 
forms that are prone to regulation. Figure and legend from (Pop and Salvesen, 2009). 
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1.4 Mitochondrial-induced apoptosis 
 
Mitochondria play a pivotal role in the cascade of events in cell death (Perkins et al., 2009), 
and B-cell lymphoma 2 (Bcl-2) family proteins are particularly important in the mitochondrial 
pathway. These proteins are subdivided in two groups: anti-apoptotic and pro-apoptotic. The 
first group includes Bcl-2 and B-cell lymphoma-extra large (Bcl-XL), and the second group 
includes Bcl-2-associated X-protein (Bax), Bcl-2 family antagonist (Bak) and Bcl-associated 
death promoter (Bad). The mitochondrial pathway involves the upregulation and translocation 
of the pro-apoptotic proteins Bax and Bak to the mitochondrial outer membrane, and this 
translocation leads to conformational changes and the oligomerisation of the outer 
mitochondrial proteins that increase mitochondrial outer membrane permeability (Figure 4). 
This process results in the release of cyt c, AIF and Smac/DIABLO, which trigger caspase 9 
activation, thereby activating effector caspase 3, which results in the cleavage of numerous 
protein substrates. Anti-apoptotic proteins such as Bcl-2 and Bcl-XL prevent the release of cyt 
c from the mitochondria, and Bcl-XL also prevents caspase 9 activation by interacting with 
APAF-1 (Fan et al., 2005). 
1.5 Reactive oxygen species 
 
ROS is a collective term used for O2-derived free radicals such as superoxide anions (O2.-) and 
hydroxyl (OH.), peroxyl (RO2.) and alkoxyl (RO.) radicals as well as O2-derived nonradical 
species such as hydrogen peroxide (H2O2). Mitochondria are a major source of intracellular 
ROS (Circu and Aw, 2010) that are generated via mitochondrial respiration during the 
reduction of molecular oxygen as well as by distinct enzymatic systems. ROS have been 
implicated in the regulation of diverse cellular functions including pathogen defence, 
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intracellular signalling, transcriptional activation, proliferation and apoptosis (Davis et al., 
2001). Many cytotoxic drugs increase intracellular oxidative stress, which results in apoptosis. 
The cellular response to cytotoxic agents may generate ROS in excess of the levels of thiol 
buffers and other antioxidants, which may activate mitochondria (Figure 4). ROS may also 
activate other signalling pathways, e.g., through the stress kinase cascade. Alternatively, 
cytotoxic agents may modulate the compartmentalisation of GSH. In this scenario, although 
ROS are not generated directly, the loss of nuclear GSH may activate downstream proteolytic 
caspases that result in cell death (Davis et al., 2001). 
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Figure 4. Mitochondrial membrane permeabilisation (MMP) can be generated by either of 
two distinct, but partially overlapping, molecular mechanisms. On the one hand, large 
channels formed by multidomain pro-apoptotic proteins from the BCL-2 family (for example, 
BCL-2-associated protein X (BAX) or BCL-2 antagonist/killer (BAK) might selectively 
promote mitochondrial outer membrane permeabilisation (MOMP) (a). On the other hand, 
cell death inducers such as Ca2+ overload and oxidative stress trigger MMP at the inner 
mitochondrial membrane (IM) by favouring the opening of the permeability transition pore 
complex (PTPC). This process is known as the mitochondrial permeability transition 
(MPT)(b). Anti-apoptotic proteins from the BCL-2 family (for example, BCL-2 and BCL-XL) 
reportedly inhibit both MOMP and MPT. Similarly, the pro-apoptotic BCL-2 protein BAX 
mediates MOMP but can also bind to PTPC components such as adenine nucleotide 
translocase (ANT) and the voltage-dependent anion channel (VDAC) to favour MPT (inserts). 
BCL-2 homology domain 3 (BH3)-only proteins and p53 provide an additional, upstream 
level of control to MMP. Some BH3-only proteins (also known as activators; for example, 
BID and BIM (also known as BCL-2-like protein)) can directly interact with BAX and BAK, 
thereby triggering their pore-forming function. By contrast, so-called sensitisers (for example, 
BAD and HRK (also known as DP5)) promote MMP by disrupting the inhibitory interactions 
between anti-apoptotic BCL-2 proteins and BAX, BAK, activators or PTPC components. p53 
might exert lethal functions on mitochondria by mimicking the activity of BH3-only proteins 
at multiple levels. Figure and legend from (Galluzzi et al., 2009). 
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1.6 Zinc deprivation 
 
Zinc is essential for cell differentiation and proliferation, especially for DNA synthesis and 
mitosis (Beyersmann and Haase, 2001). Zinc is an integral part of many proenzymes in cells 
and may function as a cofactor. Zinc deficiency induces apoptosis though the intrinsic 
mitochondrial pathway, which can be triggered by the zinc-regulated enzyme caspase-3 and 
as a consequence of abnormal regulation of pro-survival signals (ERK1/2 and NF-Kappa B) 
in neurons (Adamo et al., 2010) (Figure 5). 
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Figure 5. Proposed mechanisms for Zn-deficiency-induced decrease in cell proliferation 
and induction of apoptosis. Solid or dotted lines indicate proposed mechanisms leading to 
neuronal cell cycle arrest, decreased proliferation and induction of apoptosis as a consequence 
of a decreased Zn availability. Figure and legend are modified from (Adamo et al., 2010). 
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1.7 MEK/ERK-signalling pathway  
 
There is a controlled balance between cell death and survival that may be affected by the cell's 
external environment (Henson and Gibson, 2006). MAP kinases have a central role in signal 
transduction cascades triggered by extracellular substances such as hormones, 
neurotransmitters and growth factors that regulate various cellular processes (Seger and Krebs 
1995). The MAP kinase cascade consists of several protein kinases that specifically 
phosphorylate and activate each other (Chuderland and Seger, 2005) (Figure 6). The 
MEK/ERK signalling pathway is a part of this cascade and plays important roles in 
proliferation, differentiation and survival. The MEK/ERK signalling pathway is affected by 
numerous factors such as serum nutritional content, growth factors and various types of stress 
(Seger and Krebs, 1995; Lewis et al., 1998). The MEK/ERK-phosphorylation cascade starts 
with a ligand binding to a transmembrane tyrosine kinase receptor on the cell surface. This 
binding leads to the activation of the G-protein Ras, which recruits Raf kinase that 
phosphorylates and further activates MEK, which then activates ERK (Shaul and Seger, 
2007). Activated ERK can interact with cytosolic substrates or translocate to the nucleus and 
regulate various transcription factors, kinases and cytoskeleton proteins with different 
interacting proteins (Lewis et al., 1998; Shaul and Seger, 2007) (Figure 6). The duration of 
activation is also important; it has been shown in PC12 cells that nerve growth factor (NGF) 
promotes differentiation via strong and sustained ERK activation, whereas epidermal growth 
factor (EGF) promotes proliferation through strong and transient ERK activation (Nguyen et 
al., 1993). ERK blocks caspase-9 activation by direct phosphorylation and also inhibits 
caspase-3 activation and apoptosis (Allan et al., 2003). EGF acts as one of the many sensors 
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controlling the degree of apoptotic signalling within the cell (Henson and Gibson, 2006). EGF 
signalling enhances survival responses in cancer cells. When the EGF survival signalling 
pathway is targeted, cancer cells undergo apoptosis or become sensitive to radiation and 
chemotherapy.  
 
Figure 6. MEK/ERK-signalling pathway. Growth factors and other extracellular ligands bind 
to a transmembrane receptor that dimerises and phosphorylates tyrosine residues. SH2-
domain-containing adaptor proteins such as Grb2 bind to the phosphorylated tyrosine residues 
and recruit SOS receiving Ras to convert GDP to GTP and become activated. Ras 
phosphorylates and activates Raf, which in turn phosphorylates and activates MEK, which 
then phosphorylates and activates ERK. ERK binds to and activates substrates in the cytosol 
and translocates to the nucleus, where it activates various transcription factors. Figure and 
legend are modified from (Seger and Krebs, 1995; Henson and Gibson, 2006). 
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1.8 Apoptosis-inducing compounds 
 
There are many compounds that may initiate apoptosis via the intrinsic or extrinsic pathway 
in cancer cells and non-cancerous cells. Small molecules are under development to target the 
apoptotic cascade (Putt et al., 2006). These molecules may be used as anticancer agents or 
tools to study caspase functions.  
1.8.1 Caspase-3 activators 
 
Caspase activation by small molecules such as PAC-1 and 1541 has emerged as a powerful 
anticancer strategy. These molecules are known to transform procaspase-3 (inactive zymogen) 
to active caspase-3 directly in cancerous cells (Putt et al., 2006), which is a hallmark process 
of apoptosis.  
1.8.2 PAC-1  
 
PAC-1 was the first procaspase-3 activating compound to be discovered by high-throughput 
screening in 2006 (Putt et al., 2006). It was originally thought that PAC-1 directly 
transformed procaspase-3 to caspase-3 in vitro and induced apoptosis in cancerous cells 
isolated from primary colon tumours in a manner directly proportional to the cellular 
concentration of procaspase-3 (Putt et al., 2006). However, several mechanisms for the 
activation of caspase-3 by PAC-1 have since been proposed, including the sequestration of 
inhibitory zinc ions (Figure 7). Zinc is as an endogenous caspase-3 inhibitor and anti-
apoptotic agent, which suggests a shared mode of action for certain zinc-chelating anti-cancer 
compounds (Peterson et al., 2009a),(Peterson et al., 2009b). PAC-1 binds to zinc, 
enzymatically activating procaspase-3 and allowing the subsequent activation of another 
molecule of procaspase-3 to form caspase-3 (Peterson et al., 2009a). Zinc chelation is an 
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important mechanism to reduce cell proliferation and induce apoptosis (paper I). However, 
because PAC-1 is not able to fully activate procaspase-3, its potential as an anticancer drug 
may not be very promising (Wolan et al., 2009). 
PAC-1 was found to be neurotoxic in chicken CGN (Paper I) and dogs (Peterson et al., 2010). 
The neurotoxic properties of PAC-1 raised challenges for its use as an anticancer drug and led 
to the development of S-PAC-1, which contains a polar sulfonamide on the benzyl ring of 
PAC-1. This compound is believed to have a similar procaspase-3 activating ability, but 
because it cannot cross the blood-brain barrier, it is not neurotoxic in mice or dogs (Peterson 
et al., 2010). 
The phenolic hydroxyl group of the PAC-1 molecule is important for caspase activation and 
zinc chelation. PAC-1 derivatives lacking this group do not activate procaspase-3 in vitro and 
do not induce death (Peterson et al., 2009b) (paper I). It is also known that ortho-hydroxy N-
acyl hydrazones, which are a part of the PAC-1 molecule, bind to metal ions and are essential 
for zinc binding. Any modification of this structure will result in compounds that are unable 
to bind zinc or activate caspase-3, which means they would be unable to induce cell death 
(Peterson et al., 2009b). Conversely, other sites on PAC-1, such as the benzyl ring, could be 
altered without affecting either activity (Peterson et al., 2009b). 
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Figure 7. The proposed mechanism for PAC-1-induced activation of procaspase-3 in 
vitro. Zinc inhibits the catalytic activity of procaspase-3, PAC-1 binds tightly to zinc, and 
PAC-1 relieves the zinc-mediated inhibition of procaspase-3. This zinc sequestration enables 
procaspase-3 to function as an enzyme and proteolytically cleave another molecule of 
procaspase-3, converting it to caspase-3. Figure is from (Peterson et al., 2009a). 
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1.8.3 Proenzyme activator 1541  
 
After the discovery of PAC-1, another small-molecule activator of procaspase-3 was 
introduced in 2009 and considered as a direct activator (Figure 8). Proenzyme activator 1541 
bypasses the upstream pro-apoptotic signalling pathway and induces rapid apoptosis in a 
variety of cell lines (Wolan et al., 2009). When compared with granzyme B, which is a 
natural activator of procaspase-3, 1541 induced accelerated activation of caspase-3 to a level 
that was finally 70% that of granzyme within 2.5 hours. Granzyme B and 1541 both induced 
full proteolytic cleavage of procaspase-3 into large (17 kD) and small (12 kD) subunits of 
caspase-3. 1541 promoted the activation and self-processing of procaspase-3 and procaspase-
6. 1541 did not activate procaspase-1 and procaspase-7 and was considered to be an excellent 
activator of procaspase-3 in a variety of cancer cells that are resistant to pro-apoptotic stimuli 
(Wolan et al., 2009). When compared with PAC-1, 1541 was significantly better at activating 
procaspase-3 (Wolan et al., 2009).  
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Figure 8. Proposed model for small-molecule-assisted procaspase self-activation. 
Procaspases are hypothesised to be in a dynamic equilibrium between an off-state (left) and 
on-state. Binding of a small-molecule activator shifts the equilibrium to an on-state (centre). 
This complex slowly undergoes autoproteolytic activation (black arrows) that accelerates with 
the increased production of the mature caspase (green arrows). This model also accounts for 
activation at low concentrations of the small molecule where the on-state is preferred, one 
active site is available in the dimer for processing and, at high concentrations, where both 
sites are saturated and can lead to inhibition. Figure and legend are modified from (Wolan et 
al., 2009).  
 
 
 
1.8.4 CA-4 and analogues 
 
The combretastatins are small natural products isolated from the bark of the African bush 
willow tree, Combretum caffrum. CA-4, which is a phenolic cis-stilbene natural product, has 
entered several clinical trials as a potential anticancer drug (Kanthou and Tozer, 2009). 
Whereas PAC-1 and 1541 are thought to activate caspases directly, CA-4 is an indirect 
caspase activator. Several of its analogues have been shown to have cytotoxic effects. 
Recently, certain 1,5-disubstituted 1,2,3-triazole analogues of CA-4 with the two aryl groups 
retained in the cis-configuration were reported to display potent cytotoxic activity against 
several human cancer cell lines (Odlo et al., 2008) (Odlo et al., 2010). A CA-4 analogue 
promotes apoptosis in chondrosarcoma cells by inducing mitochondrial dysfunction through a 
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caspase-9- and caspase-3-mediated mechanism (Liu et al., 2011). CA-4 induces cell death in 
the H460 lung cancer cell line via activation of the mitochondrial signalling pathway (Mendez 
et al., 2011).  CA-4 and analogue 2 are potent tubulin inhibitors and are highly toxic to cancer 
cells. Little is known about analogue 3 as a tubulin inhibitor (Odlo et al., 2010). ERK 1/2 
were shown to protect against blebbing induced by CA-4-phosphate (CA-4-P), which was 
associated with decreased viability in human endothelial cells (Kanthou and Tozer, 2002).  
In paper III, 1,5-disubsituted 1,2,3 triazole analogues of CA-4 were studied to shed light on 
their structure-activity relationships and pharmacological mechanisms. Analogue 2 has a cis 
configuration and a phenolic hydroxyl group, analogue 3 lacks a phenolic hydroxyl group and 
analogue 4 has a trans configuration.   
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2. Discussions of Methods 
 
2.1 Primary cultures of chicken CGN and PC12 cells 
  
The cerebellum is a prominent brain structure in most mammals, and most of its neurons are 
granule cells that are located in the deepest layer. CGN primary culture has been used for 
many years and is a recognised model for studying neuronal development, function and 
pathology (Henson and Gibson, 2006). Chicken CGN are an economical and simple 
alternative to mouse or rat CGN. In chicks, CGN are formed the last week before hatching by 
intense mitotic activity in the outer granule layer of cells followed by migration to the inner 
cell layer. Isolation of CGN on embryonic day 18 has been shown to provide a good yield. 
Chicken CGN develop excitotoxicity with ROS production and caspase-3 activation after 3 
days in vitro and can be used as a model in studies of the mechanisms involved in apoptosis 
(Jacobs et al., 2006) (Paper I and Paper II). PC12 cells are a neuroendocrine cell line derived 
from a phaeochromacytoma in the rat adrenal medulla (Trujillo, 2011). The growth of PC12 
cells in serum-containing medium results in a round or angular morphology. At a high cell 
density, they become more rounded, and the cells clump together (Kanthou and Tozer, 2002). 
PC12 cells are a good model for studying signalling pathways because specific responses to 
differentiation, proliferation and survival can be studied independently, and there are few 
growth factors and hormones that the cells do not respond to. This cell line has been used to 
study the MEK/ERK-signalling pathway, and stimulation with EGF was shown to lead to 
proliferation (Vaudry et al., 2002). These cells have properties similar to those of sympathetic 
neurons and form long projections upon NGF stimulation. They are a useful model to study 
the nervous system at the cellular and molecular levels (Trujillo, 2011). Several 
pharmacological and biochemical substances induce death in PC12 cells (Kanthou and Tozer, 
2002), including PAC-1, which has been shown to induce cell death via procaspase-3 (Putt et 
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al., 2006). Therefore, PC12 cells can also be used as a model to study cell death mechanisms 
(Paper I, Paper II and Paper III). 
2.2 Cell death  
 
Cell death mechanisms have been investigated in PC12 cells and chicken CGNs. There are 
different advantages and disadvantages for each culture type. PC12 (dividing cells) and CGNs 
(post-mitotic cells) have similar levels of procaspase-3 (Paper I), which is one of the reasons 
for choosing these two models to study cell death. Interestingly, PAC-1 has similar EC50 
values in the two cell types (paper I). PAC-1 induces caspase-3-dependent cell death in 
different cancer cell lines (Putt et al., 2006).  
Several methods are used to measure cell viability, each based on different principles, 
including cell morphology, membrane permeability and mitochondrial activity (Aras et al., 
2008). Cell death in CGN and PC12 cells was measured with the Trypan Blue exclusion 
assay. Live cells have intact cell membranes that are impermeable to Trypan Blue; dead cells 
have ruptured membranes that are permeable to the dye. The number of blue cells was 
counted manually. Cell death can also be measured by the LDH release and MTT assays. 
However, the trypan blue exclusion assay is more reliable because cell division does not 
influence the outcome, and it has the added advantage of providing morphological 
information about the cells.  
Propidium iodide staining and subsequent fluorescent microscopy analysis would have 
contributed additional information about nuclear morphology. 
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2.3 Caspase-3 activation and detection 
 
Several different methods are used to measure activated caspase-3 (Paroni and Brancolini, 
2011). The detection of caspase activation is essential to investigate several biological 
processes and can be used as biochemical marker for apoptosis induced by diverse stimuli 
(Vaculova and Zhivotovsky, 2008). Caspase activation can be detected by measuring caspase 
activity, the release of cyt c, or cleaved caspases by western blot analysis (Krysko et al., 
2008). For these studies, a caspase-3 activity assay was used to measure cellular responses to 
the different apoptosis inducers PAC-1 and 1541 as well as CA-4 and its analogues. A 
specific caspase-3 substrate (Z-DEVD2 Rhodamine 110) was used, and RFU values were 
measured by Bio assay readers. This method is advantageous because it is fast, and the RFU 
values are directly proportional to the activity inside the cells. Western blot analysis is a 
reliable method for detecting and characterizing specific proteins in complex extracts; 
however, quantification is more difficult with this method (Paper I) (Tovey et al., 1987).  
2.4 ROS  
 
The vulnerability of some cells to oxidative signals is a therapeutic target for rationally 
designed anticancer agents. In addition to their well-characterised effects on cell division, 
many cytotoxic anticancer agents can induce oxidative stress by modulating levels of reactive 
oxygen species such as superoxide anion radical, hydrogen peroxide and hydroxyl radicals 
(Montero and Jassem, 2011). Thus, it is important to understand the roles of different ROS 
generated in response to diverse apoptosis-inducing stimuli. The ideal chemical ROS probe 
would be highly reactive at low concentration, specific, non-toxic, chemically well-
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characterised and easy to load into the cells without unwanted diffusion, excretion or 
metabolism (Wardman, 2007).  
 
2.4.1 Measurement of ROS production 
 
ROS production in cells can be quantified by using ROS-specific probes that penetrate the 
cell membrane and generate a fluorescent signal upon oxidation. These studies employed 
dihydrorhodamine (DHR) and dihydroethidium (DHE) to measure ROS (Paper III). DHR is 
cell-permeant with a particular affinity for mitochondria. DHR is subsequently oxidised to 
fluorescent rhodamine 123, which is more specific for peroxynitrite (Wilhelm et al., 2009). 
DHE undergoes a two-electron oxidation to form a DNA-binding fluorophore. In the case of 
mitochondrial generation of superoxide, DHE binds to mitochondrial DNA, and at higher 
concentrations, it also binds to nuclear DNA. DHE is oxidised into two fluorescent products, 
2-hydroethidium, which is more specific to superoxide and ethidium (Wilhelm et al., 2009). 
CA-4 and its triazole analogues increased intracellular oxidative stress in PC12 cells as 
measured by DHR and DHE fluorescence. CA-4 and its triazole analogue 2 oxidised both 
DHR and DHE, whereas analogue 3 only oxidised DHE, which indicates that CA-4 and its 
triazole analogues produce different types of ROS (paper III). MT Red CM-H2XROS is cell-
permeant, oxidised inside the mitochondria and can also be used to investigate mitochondrial 
ROS generation.  
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2.4.2. ROS scavenging 
 
The synergistic ability of vitamins C and E to scavenge toxic ROS was studied (paper III). 
These scavengers reduced cell death induced by CA-4 and its analogues, which demonstrates 
that ROS are involved in cell death. DHE protected against CA-4 and triazole analogues 2 and 
3, whereas DHR protected against CA-4 and analogue 2. These results show that vitamins as 
well as DHE and DHR alone or in different combinations can be used as ROS scavengers 
(paper III). This study also highlights the death mechanism involved. 
2.5 Pharmacological inhibitors 
 
Caspase-3 activation by PAC-1, CA-4 and triazole analogue 2 was detected with a caspase-3 
substrate (Z-DEVD2 Rhodamine 110), and A caspase-3 inhibitor was used as a negative 
control. In the cell death assay, the caspase-3 inhibitor was used to block caspase-mediated 
cell death by PAC-1 and 1541 as well as CA-4 and its triazole analogues 2 and 3. Most 
commercially available caspase substrates and inhibitors lack the specificity required to 
monitor individual activity; it is difficult to differentiate among caspase-3 -6 and -7 (Berger et 
al., 2006; Pereira and Song, 2008). For this reason, an MEK inhibitor (U0126) was also used. 
The MEK kinases are unique in that they show very high specificity to ERK; in fact, ERK is 
the only substrate for MEK. Therefore, blocking MEK from phosphorylating ERK only 
affects ERK activation (Trujillo, 2011).  
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3. Discussion of Results 
 3.1 PAC-1, 1541, CA-4 and analogues induce cell death  
 
Papers I and II showed that PAC-1 and 1541 induce cell death in chicken CGN and PC12 
cells. These results are consistent with previous studies using different cancer cell lines (Putt 
et al., 2006; Wolan et al., 2009). PAC-1 was initially introduced as a direct activator of 
procaspase-3, and later an alternative mechanism was proposed that PAC-1 activates 
procaspase-3 into caspase-3 via the chelation of inhibitory zinc (Peterson et al., 2009a). It was 
possible to protect against PAC-1 induced cell death in PC12 cells by adding 10 µM ZnSO4 
(unpublished), which supports a zinc-dependent mechanism. However, later studies showed 
that PAC-1 also induces cell death in MCF-7 cells that do not express procaspase-3 (Putt et 
al., 2006; Denault et al., 2007), which indicates additional mechanisms. Both EGF (paper II) 
and ROS scavenging (unpublished) yielded a small reduction in cell death. Low 
concentrations of PAC-1 increased toxicity in PC12 cells exposed for longer periods of time 
(paper I). 
1541 was reported to be a more specific caspase-3 activator than PAC-1. It directly activates 
the catalytic domain of procaspase-3 and stabilises an active conformation of the enzyme 
(Wolan et al., 2009; Zorn and Wells, 2010). However, 1541 showed results similar to those of 
PAC-1 in both chicken CGN and PC12 cells. 
In paper III, CA-4 and its triazole analogues were studied in PC12 cells. CA-4 has been 
reported as a potent anticancer agent against a variety of human cancer cells including 
multidrug-resistant cancer cells (Nam, 2003). CA-4 and its triazole analogues 2 and 3 were 
toxic to PC12 cells at 1 µM and 10 µM. CA-4 and its triazole analogue 2 activated caspase-3 
as shown in the caspase-3 activity assay. Similarly, treatment with a caspase-3 inhibitor 
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protected against CA-4- and analogue-2-induced cell death, whereas the effect of analogue 3 
was not caspase-3-dependent. This finding provides evidence that CA-4 and its triazole 
analogue 2 are caspase activators. This caspase activation was linked to an ROS molecule that 
could be blocked by DHR (paper III). 
3.2 CA-4 and analogue 2 induce caspase-3 and ROS-dependent cell death 
 
CA-4 and its triazole analogue 2 induce cell death via caspase-3 activation and ROS 
production. The effect of CA-4 and its analogues on ROS production has previously not been 
well documented. DHE and DHR are specific probes used to detect superoxide and 
peroxynitrite, respectively (Wardman, 2007). Together with the results obtained from the slot 
blot analysis of the nitrotyrosination of proteins, which is a modification that is thought to 
result from the reaction of peroxynitrite with proteins (Ischiropoulos, 1998), the results in 
paper III support peroxynitrite formation following treatment with CA-4 and analogue 2. 
Results from ROS assays with MT Red CM-H2XROS, which is oxidised to a fluorescent 
product inside the mitochondria, indicate that ROS are mainly produced in the mitochondria; 
these species trigger the downstream caspase cascade and cell death (unpublished). 
3.3 Crosstalk between ROS production and caspase-3 cascade 
 
ROS production may be primary or secondary to caspase-3 activation. Mitochondria- 
generated ROS play an important role in release of cyt c and other pro-apoptotic proteins that 
can trigger caspase activation and apoptosis (Ott et al., 2007). Many anticancer agents 
function in a similar way, with effects specific to cancer cells (Orrenius et al., 2007). To 
investigate the crosstalk between ROS and caspase cascades, we utilized different ROS 
probes, including DHE, DHR, MT Red CM-H2XROS and a caspase-3 inhibitor. CA-4 and 
analogue 2 appear to produce toxic ROS that activate caspase-3 and cell death (Paper III). 
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However, the caspase-3 inhibitor reduced ROS, which suggests that signalling pathways are 
bidirectional.  
3.4 Growth factors prevent cell death induced by PAC-1 and 1541 
 
The results presented in Paper II show reduced PAC-1- or 1541-mediated cell death when 
PC12 cells are treated with EGF, and these results are further augmented by the addition of 
MEK inhibitor. It is known that EGF can protect against cell death through the activation of 
the MEK/ERK-signalling pathway, which regulates the transcription or function of apoptotic 
or anti-apoptotic proteins (Henson and Gibson, 2006). EGF also stimulates the proliferation of 
PC12 cells through the strong and transient activation of ERK (Sasagawa et al., 2005). 
Similar results were obtained in chicken CGN. These results raise challenges to the use of 
direct caspase activators as anticancer therapeutic agents. 
3.5 Crosstalk between the MEK/ERK signalling pathway and the caspase cascade 
 
It has been shown that EGF reduces PAC-1-induced caspase-3 activity in PC12 cells. If PAC-
1 is a direct activator of caspase- 3, then caspase-3 depends on upstream mechanisms even 
when it is activated directly. EGF may up-regulate IAP, which directly inhibits caspase-3 and 
other caspases (Deveraux et al., 1999; Henson and Gibson, 2006). It is also known that EGF 
can down-regulate upstream caspase-9. A third possibility is that PAC-1 does not activate 
caspase-3 directly, which is supported by cell death in MCF-7 cells that do not express 
caspase-3 (Denault et al., 2007). However, 1541-induced cell death was also reduced by EGF, 
which suggests a common mechanism. 
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4. Concluding remarks 
 
The results presented in this thesis show that:  
 Both PAC-1 and 1541 induce cell death in CGN and PC12 cells. 
 PAC-1 is a zinc chelator in vitro and kills cells by a mechanism that is partly 
dependent on caspase-3. 1541 seems to have similar effects in cells but has not 
proven to be a more specific activator of caspase-3 than PAC-1. The crosstalk 
between the caspase cascade and the MEK/ERK-signalling pathway makes it difficult 
for the compounds to specifically interact with caspase-3.  
 Agents such as PAC-1 and 1541 can be used to study apoptosis mechanisms in cell 
models of apoptosis regulation and as potential pharmacological treatments. 
 CA-4 and its triazole analogues 2 and 3 are toxic to PC12 cells, and this toxicity is 
derived for ROS production and caspase-3 activation, which lead to cell death. 
 PC12 and chicken CGN are useful models to study cell death induced by PAC-1, 
1541 and CA-4 and its triazole analogues. 
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